Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 141 of 5804
-
New combo therapy targets stubborn nasopharyngeal cancer in phase 3 trial
Disease control Not yet recruitingThis trial evaluated the efficacy of two adjuvant regimens following identical induction and concurrent chemoradiotherapy (IC+CCRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients with persistent EBV DNA positivity or stable disease after three IC cycles. The…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Immune boosters take on brain cancer: new trial launches
Disease control Recruiting nowGIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in …
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug TAK-928 takes on tough lung cancer in major trial
Disease control Recruiting nowLung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses on NSCLC in later stages (advanced). This …
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo therapy aims to spare bladders in cancer patients
Disease control Recruiting nowThis phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy includes chemotherapy before surgery (neoadj…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New immunotherapy cocktail aims to stall pancreatic cancer after chemo
Disease control Recruiting nowPhase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-8 months of first line (1L) chemotherapy.
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a Weight-Loss drug cure sleep apnea without a machine?
Disease control Recruiting nowThis Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for kids with rare epilepsy: first human trial launches
Disease control Recruiting nowStudy CL1-230815-001 (KANDLE) is a Phase Ib/II, First In Human, multicentre, open-label, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effect of S230815 in pediatric participants with KCNT1-related Developmental E…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill could help kids with dwarfism grow better
Disease control Recruiting nowThis is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Ph…
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Spinal stimulation may reawaken paralyzed arms — a trial puts it to the test
Disease control Recruiting nowThis study aimed to determine whether cervical spinal cord epidural electrical stimulation (EES) can activate upper-limb muscles in individuals with spinal cord injury.
Phase: NA • Sponsor: Buddhist Tzu Chi General Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New eye implant could slow vision loss in diabetes
Disease control Recruiting nowThe purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy. OTX-TKI is an intravitreal hydrogel embedded with axitinib. When the OTX-TKI hydrogel is administered into …
Phase: PHASE3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a 90-Minute session curb suicidal thoughts? new trial aims to find out
Symptom relief Recruiting nowThe goal of this project is to assess the efficacy of Brief-Skills for Safer Living (Brief-SfSL) in a randomized control trial. The investigators will be testing 150 participants Canada-wide, half of which will be randomized to receive Brief-SfSL (B-TAU) and the other half will b…
Phase: NA • Sponsor: Unity Health Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New mRNA shingles vaccine shows promise in Mid-Stage trial
⭐️ VACCINE ⭐️ OngoingThe primary objective of this study is to evaluate the immunogenicity and safety of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
Phase: PHASE2 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:31 UTC
-
New cocktail aims to stall breast cancer spread in Hard-to-Treat cases
Disease control Recruiting nowThis study is an open-label, multicenter, randomized controlled study. It is planned to include 258 patients with HR +/HER2- advanced breast cancer with visceral metastases. Eligible subjects will be randomized 1:1 to receive dalpiciclib in combination with endocrine therapy and …
Phase: PHASE3 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a quick blood thinner before stroke surgery boost recovery?
Disease control Recruiting nowIt remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tiro…
Phase: PHASE3 • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo before liver surgery aims to stop cancer return
Disease control Recruiting nowThis is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New shot could help patients with severe blistering skin disease ditch steroids
Disease control Not yet recruitingThis study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.
Phase: PHASE3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Lung cancer trial aims to match treatments to tumor type
Disease control Recruiting nowThis phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more informat…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on brain cancer in pioneering trial
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
First gene therapy for rare brain disorder begins testing in kids
Disease control Recruiting nowThe goal of this first in human, phase I/II clinical trial is to evaulate the safety, tolerability, and preliminary efficacy of AAV9 mediated gene replacement therapy (Urbagen) in paediatric patients with CTNNB1 neurodevelopmental disorder. The main questions it aims to answer ar…
Phase: PHASE1, PHASE2 • Sponsor: CTNNB1 Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug aims to outsmart recurrent lymphoma
Disease control Not yet recruitingEvaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC